Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 504 participants.

Also called NCT02849080

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 504 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02849080
  • EudraCT 2015-005593-38
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial The lancet. Diabetes & endocrinology, 2019-07 DOI, PubMed 31189520 PubMed links an erratum for this paper. Erratum: PMID 31320282
  • Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial BMJ open diabetes research & care, 2020-12 DOI, PubMed 33318068, PMC7737050 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Egypt, Norway, South Korea, Switzerland, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02849080. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2018-02-28 (actual). Results posted on 2020-02-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
Acronym
PIONEER 7
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
sitagliptin
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02849080
Content hash
3d855b530c59917bb9c8a0dfe74dec3b58a97b0b1ef57e14b4fa933dc322c20a